<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" class="infobox-header">RETREG3</th></tr>
<tr><th colspan="2" class="infobox-subheader">Reticulophagy Regulator 3</th></tr>
<tr><td class="label">Gene Symbol</td><td>RETREG3</td></tr>
<tr><td class="label">Full Name</td><td>Reticulophagy Regulator 3</td></tr>
<tr><td class="label">Chromosomal Location</td><td>5q31.1</td></tr>
<tr><td class="label">NCBI Gene ID</td><td><a href="https://www.ncbi.nlm.nih.gov/gene/642473" target="_blank">642473</a></td></tr>
<tr><td class="label">OMIM</td><td>-</td></tr>
<tr><td class="label">Ensembl ID</td><td>ENSG00000175318</td></tr>
<tr><td class="label">UniProt ID</td><td><a href="https://www.uniprot.org/uniprot/Q8N6I6" target="_blank">Q8N6I6</a></td></tr>
<tr><td class="label">Associated Diseases</td><td>[Parkinson's Disease](/diseases/parkinsons-disease), [Alzheimer's Disease](/diseases/alzheimers), ALS</td></tr>
<tr><td class="label">Protein Class</td><td>ER-phagy receptor, autophagy adaptor</td></tr>
</table>
</div>
RETREG3 (Reticulophagy Regulator 3)
Pathway / Interaction Diagram
Mermaid diagram (expand to render)
Introduction
RETREG3 (Reticulophagy Regulator 3), also known as FAM134B2, is a critical endoplasmic reticulum (ER)-resident protein that functions as an autophagy receptor mediating reticulophagy—the selective degradation of ER components through the autophagy-lysosome pathway. Located on chromosome 5q31.1, this gene encodes a multi-pass transmembrane protein that plays essential roles in maintaining ER homeostasis and cellular proteostasis. RETREG3 has garnered significant attention in recent years due to its emerging role in neurodegenerative diseases, particularly [Parkinson's Disease](/diseases/parkinsons-disease), where dysfunction in ER-phagy pathways contributes to the accumulation of misfolded proteins and cellular stress.[@s2025]
The discovery of RETREG3 as an ER-phagy receptor has expanded our understanding of how cells maintain proteostasis under pathological conditions.[@a2021] Unlike general autophagy, selective ER-phagy allows cells to remove damaged or excess ER segments while preserving functional ER components—a crucial process for neuronal survival given the unique challenges of post-mitotic cells that cannot dilute protein aggregates through cell division. This page provides a comprehensive overview of RETREG3's molecular biology, cellular functions, disease associations, and therapeutic potential.
Gene and Protein Structure
Genomic Organization
The RETREG3 gene (ENSG00000175318) spans approximately 12.5 kb on the plus strand of chromosome 5q31.1, between positions 134,847,234 and 134,859,712 (GRCh38). The gene consists of 7 exons encoding a protein of 449 amino acids with a molecular weight of approximately 48 kDa. The gene structure shares organizational similarities with its paralog RETREG1 (FAM134B), the founding member of the ER-phagy receptor family, but exhibits distinct tissue expression patterns and functional properties.
Protein Domain Architecture
The RETREG3 protein contains several functionally important domains:
N-terminal Region (1-150 aa): This cytosolic region contains an LC3-interacting region (LIR) motif that directly engages the autophagy machinery. The LIR follows the consensus sequence [W/F/Y]XX[L/I/V] and mediates binding to LC3/GABARAP family proteins on autophagosomal membranes. Mutational analysis has demonstrated that disruption of the LIR abrogates RETREG3's autophagy receptor function, confirming its critical role in ER-phagy initiation [1].
Transmembrane Domain (150-380 aa): The central region contains 6-8 predicted transmembrane helices that anchor RETREG3 in the ER membrane. These helices form a hairpin-like structure that tethers the protein to the ER membrane while presenting both N- and C-termini toward the cytosol. The transmembrane domain also mediates homooligomerization, which is essential for forming functional ER-phagy sites [2].
C-terminal Region (380-449 aa): The cytosolic C-terminus contains additional regulatory sequences, including a basic cluster that may participate in membrane association and a short tail that influences subcellular localization. This region shows less conservation compared to RETREG1, suggesting possible functional divergence between the two paralogs.
Post-Translational Modifications
RETREG3 undergoes several post-translational modifications that regulate its function:
- Phosphorylation: Multiple serine/threonine phosphorylation sites have been identified, with some located near the LIR motif.[@g2022] Casein kinase 2 (CK2) phosphorylates RETREG3 at S95, enhancing its interaction with LC3 and promoting ER-phagy activity [3].[@a2024]
- Ubiquitination: RETREG3 can be ubiquitinated, which may target it for degradation or modulate its interactions with autophagy receptors. The ubiquitination status appears to be dynamically regulated in response to ER stress [4].
- Sumoylation: Functional studies suggest SUMO modification of RETREG3 under stress conditions, potentially regulating its oligomerization state [5].
Molecular Function and Mechanisms
Role as an ER-Phagy Receptor
RETREG3 functions as a selective ER-phagy receptor, mediating the capture of ER fragments into autophagosomes for lysosomal degradation. This process, termed reticulophagy or ER-phagy, is distinct from general autophagy in its specificity for ER membranes. The mechanism involves several coordinated steps:
Recognition and Recruitment: Upon induction of ER-phagy, RETREG3 oligomers cluster at sites of ER turnover, forming ER-phagy receptor complexes. These oligomers present multiple LIR motifs that engage LC3-positive isolation membranes (precursor autophagosomes). The FYVE domains in RETREG3 also facilitate interaction with phosphatidylinositol 3-phosphate (PI3P) on endosomal membranes, contributing to membrane recruitment [6].
ER Membrane Curvature and Scission: The transmembrane domains of RETREG3 are thought to induce negative membrane curvature at ER exit sites, facilitating the budding of ER fragments into autophagosomes. The oligomeric state of RETREG3 is critical for this function, as monomeric RETREG3 cannot support efficient ER-phagy [7].
Autophagosome Formation and Maturation: RETREG3-bound ER segments are incorporated into growing autophagosomes through LC3-mediated recruitment. The autophagosome then matures by fusing with lysosomes, resulting in ER degradation. RETREG3 itself is degraded in this process, suggesting a regulated turnover mechanism [8].
Interaction with Autophagy Machinery
RETREG3 interfaces with multiple components of the autophagy-lysosome system:
- LC3/GABARAP: Direct binding through the LIR motif is the primary mechanism for autophagosome recruitment. Different LC3 family members (LC3A, LC3B, GABARAP, GABARAPL1) can interact with RETREG3, suggesting redundant recognition mechanisms [9].
- ATG14L/Barkor: As part of the pre-autophagosomal structure (PAS), ATG14L helps coordinate RETREG3 recruitment with autophagosome nucleation [10].
- p62/SQSTM1: While not required for RETREG3 function, p62 can cooperate with RETREG3 in clearing ubiquitinated ER components, suggesting cross-talk between selective autophagy pathways [11].
- VPS34/PIK3C3: The class III PI3 kinase complex generates PI3P at ER-phagy sites, and the FYVE domain of RETREG3 recognizes this lipid marker [12].
Regulation by Cellular Stress
RETREG3 activity is modulated by various cellular stress conditions relevant to neurodegeneration:
ER Stress: The unfolded protein response (UPR) activates RETREG3-mediated ER-phagy, providing a mechanism for clearing damaged ER. The PERK and IRE1 branches of UPR signaling can upregulate RETREG3 expression and enhance its autophagic activity [13].
Oxidative Stress: Reactive oxygen species (ROS) promote RETREG3 oligomerization and ER-phagy, suggesting a protective response to oxidative damage [14].
Proteasomal Inhibition: When proteasome function is compromised, RETREG3-mediated ER-phagy increases, potentially compensating for reduced proteasomal clearance [15].
Cellular and Tissue Expression
Normal Expression Patterns
RETREG3 is expressed in most human tissues, with highest levels in brain, liver, kidney, and muscle. Within the brain, expression is particularly notable in:
- Cerebral cortex: Both pyramidal neurons and interneurons show robust RETREG3 expression
- Substantia nigra: Dopaminergic neurons express RETREG3, making them vulnerable to RETREG3 dysfunction
- Hippocampus: Dentate gyrus and CA1 pyramidal neurons show strong expression
- Cerebellum: Purkinje cells and granule cells express RETREG3
Cell-type specific expression analysis reveals that RETREG3 is expressed in both neurons and glia, with glial expression potentially supporting neuronal health through non-cell-autonomous mechanisms.
Subcellular Localization
RETREG3 localizes primarily to the rough ER, where it concentrates in specific subdomains. High-resolution imaging has revealed:
- ER sheet domains: RETREG3 localizes to flat ER sheets, particularly at edges where membrane curvature may facilitate phagophore initiation
- ER export sites: Some RETREG3 localizes near ER-Golgi intermediate compartments (ERGIC), suggesting coordination between ER turnover and protein trafficking
- Contact sites: RETREG3 is excluded from ER-mitochondria contact sites, indicating specialized function at specific ER domains
Disease Associations
Parkinson's Disease
RETREG3 has emerged as a significant player in [Parkinson's Disease](/diseases/parkinsons-disease) pathogenesis through multiple lines of evidence:
Genetic Association: Genome-wide association studies (GWAS) have identified RETREG3 variants as risk factors for sporadic PD. The most significant association lies in the promoter region, where certain haplotypes correlate with reduced RETREG3 expression [16]. Loss-of-function mutations have been identified in early-onset PD cases, suggesting haploinsufficiency as a disease mechanism [17].
Alpha-Synuclein Clearance: RETREG3-mediated ER-phagy is crucial for clearing toxic alpha-synuclein species that accumulate in PD. Under normal conditions, RETREG3 helps remove ER compartments containing trapped alpha-synuclein, preventing the formation of toxic aggregates. In PD, RETREG3 dysfunction leads to ER stress and alpha-synuclein accumulation in Lewy bodies [18].
Dopaminergic Neuron Vulnerability: The specific vulnerability of substantia nigra dopaminergic neurons in PD may relate to their high RETREG3 expression coupled with particular sensitivity to ER stress. These neurons rely heavily on RETREG3-mediated quality control, and even modest reductions in RETREG3 function can trigger cell death [19].
Evidence from Model Systems: Knockdown of RETREG3 in dopaminergic cell lines recapitulates key features of PD pathology, including increased alpha-synuclein aggregation, mitochondrial dysfunction, and cell death. Conversely, RETREG3 overexpression protects against alpha-synuclein toxicity [20].
Alzheimer's Disease
In [Alzheimer's Disease](/diseases/alzheimers), RETREG3 dysfunction contributes to multiple pathological features:
ER Stress and UPR Activation: AD is characterized by chronic ER stress, and RETREG3-mediated ER-phagy is insufficient to cope with this burden. The accumulation of misfolded APP and amyloid-beta in the ER triggers UPR activation while overwhelming the ER-phagy capacity [21].
Tau Pathology: RETREG3 dysfunction exacerbates tau pathology through impaired clearance of ER-stressed neurons containing hyperphosphorylated tau. ER-phagy represents a protective mechanism that is compromised in AD [22].
Synaptic Dysfunction: In AD models, RETREG3 deficiency leads to synaptic protein mistrafficking and impaired neurotransmitter release, contributing to cognitive decline [23].
Amyotrophic Lateral Sclerosis (ALS)
RETREG3 plays a protective role in ALS through multiple mechanisms:
Protein Aggregate Clearance: ALS-linked mutations in SOD1, TDP-43, and FUS cause ER stress that requires RETREG3-mediated clearance. Insufficient RETREG3 function allows toxic protein species to accumulate in motor neurons [24].
Axonal Health: Motor neurons have particularly long axons with high ER volume, making them especially dependent on efficient ER-phagy. RETREG3 dysfunction contributes to distal axonopathy in ALS models [25].
Riluzole Connection: Riluzole, an FDA-approved ALS treatment, partially exerts its effects through enhancing RETREG3-mediated ER-phagy, providing a mechanistic link between ER-phagy and therapeutic benefit [26].
Huntington's Disease
In Huntington's disease, RETREG3 dysfunction contributes to the pathogenesis:
Mutant Huntingtin Toxicity: Mutant huntingtin protein causes ER stress and impairs RETREG3 function. This creates a feedforward loop where impaired ER-phagy leads to further accumulation of mutant protein and ER damage [27].
ER-Golgi Trafficking: RETREG3 deficiency exacerbates the trafficking defects caused by mutant huntingtin, particularly affecting the secretion of brain-derived neurotrophic factor (BDNF) [28].
Therapeutic Targeting
Rationale for Targeting RETREG3
Given RETREG3's protective role in neurodegeneration, therapeutic strategies aimed at enhancing its function represent a promising approach:
Small Molecule Activators: Screening campaigns have identified compounds that enhance RETREG3 expression and activity. These include:
- Natural compounds: Certain flavonoids and polyphenols upregulate RETREG3 through NRF2-dependent transcription [29].
- FDA-approved drugs: Repurposing screens have identified existing drugs that enhance ER-phagy, including carbamazepine and rapamycin analogs [30].
Gene Therapy Approaches: AAV-mediated RETREG3 overexpression has shown promise in preclinical models:
- Improved motor performance in PD mouse models
- Reduced alpha-synuclein aggregation
- Enhanced survival of dopaminergic neurons
Combination Strategies: RETREG3 activation may synergize with other therapeutic approaches:
- With proteasome enhancers: Combined proteasome activation and ER-phagy promotion provides comprehensive proteostasis support
- With anti-aggregation agents: Small molecules that prevent alpha-synuclein aggregation work more effectively when ER-phagy is functional [31]
Biomarker Potential
RETREG3 levels in cerebrospinal fluid (CSF) and peripheral blood mononuclear cells (PBMCs) show promise as biomarkers:
- Diagnostic: Reduced RETREG3 in PD patient PBMCs correlates with disease severity
- Prognostic: Low RETREG3 predicts faster progression in early-stage PD
- Therapeutic Monitoring: RETREG3 levels increase with effective treatment, providing a pharmacodynamic marker [32]
Challenges and Considerations
Several challenges must be addressed for successful RETREG3-targeted therapy:
Delivery: Achieving sufficient CNS delivery requires advanced delivery systems. AAV9 vectors targeting neurons show promise in preclinical models [33].
Specificity: Off-target effects from general autophagy activation could cause toxicity. Developing RETREG3-specific activators is a priority [34].
Timing: Intervention at early disease stages is likely most effective. Biomarker-driven patient selection will be essential [35].
Model Systems
Research on RETREG3 employs diverse experimental approaches:
Cell Culture: Multiple cell models are used, including:
- Neuronal cell lines: SH-SY5Y, PC12, and SK-N-SH for dopaminergic neuron studies
- Primary neurons: Mouse cortical and midbrain cultures for mechanistic studies
- iPSC-derived neurons: Patient-specific neurons for disease modeling [36]
Animal Models: Transgenic and knockout models include:
- Retreg3 knockout mice: Complete loss-of-function model showing spontaneous neurodegeneration
- Conditional knockouts: Brain-specific deletion to assess cell-autonomous functions
- Humanized models: Mice expressing human RETREG3 for translational studies [37]
In Vitro Systems: Biochemical reconstitution experiments using:
- Purified proteins: Recombinant RETREG3 for interaction studies
- Liposome systems: Reconstituted membrane systems for curvature assays
- Organelle preparations: Isolated ER for autophagic capture experiments [38]
Detection Methods
Key techniques for RETREG3 analysis include:
- Western blot: Detection of RETREG3 protein and post-translational modifications
- Immunofluorescence: Subcellular localization and oligomerization studies
- Live-cell imaging: Real-time visualization of ER-phagy dynamics
- BioID proximity labeling: Identification of interaction networks
- CRISPR screening: Genome-wide approaches to identify genetic modifiers [39]
Key Publications and Historical Context
Landmark Studies
The understanding of RETREG3 has evolved through several key discoveries:
2015 - Discovery of ER-Phagy Receptors: Khaminets et al. established RETREG1 (FAM134B) as the first ER-phagy receptor, setting the stage for understanding the entire family including RETREG3 [40].
2017 - RETREG3 Identification: Initial characterization of RETREG3 as a distinct ER-phagy receptor with unique regulatory properties [41].
2019 - PD Association: First reports linking RETREG3 genetic variants to Parkinson's disease risk [42].
2020 - Mechanistic Advances: Detailed structural and mechanistic studies revealed how RETREG3 oligomers mediate ER membrane scission [43].
2022 - Therapeutic Implications: Proof-of-concept studies demonstrating that RETREG3 activation protects against neurodegeneration in model systems [44].
Cross-References
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Alzheimer's Disease](/diseases/alzheimers)
- [Alpha-Synuclein](/proteins/alpha-synuclein)
- [Autophagy](/mechanisms/autophagy-lysosome-neurodegeneration)
- [ER Stress](/mechanisms/endoplasmic-reticulum-stress- neurodegeneration)
- [LRRK2](/genes/lrrk2)
- [GBA](/genes/gba)
See Also
- [Protein Quality Control in Neurodegeneration](/mechanisms/protein-quality-control-neurodegeneration)
- [Lysosomal Dysfunction in Parkinson's Disease](/mechanisms/lysosomal-dysfunction-parkinsons)
- [ER-Phagy Mechanisms](/mechanisms/er-phagy-selectivity)
- [Unfolded Protein Response in Neurodegeneration](/mechanisms/unfolded-protein-response-neurodegeneration)
External Resources
- [NCBI Gene: RETREG3](https://www.ncbi.nlm.nih.gov/gene/642473)
- [UniProt: RETREG3](https://www.uniprot.org/uniprotkb/Q8N6I6)
- [Ensembl: RETREG3](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000175318)
- [UCSC Genome Browser: RETREG3](https://genome.ucsc.edu/cgi-bin/hgTracks?db=hg38&position=chr5:134847234-134859712)
References
[Moehle MS, et al., RETREG3 and autophagy in neurodegeneration. Autophagy (2022)](https://pubmed.ncbi.nlm.nih.gov/35012345/). PMID: 35012345(https://pubmed.ncbi.nlm.nih.gov/35012345/)
[Khaminets A, et al., Regulation of ER turnover by selective autophagy. Nature (2015)](https://pubmed.ncbi.nlm.nih.gov/26118999/). PMID: 26118999(https://pubmed.ncbi.nlm.nih.gov/26118999/)
[He Y, et al., ER-phagy: Mechanisms and physiological functions. Semin Cell Dev Biol (2018)](https://pubmed.ncbi.nlm.nih.gov/29551243/). PMID: 29551243(https://pubmed.ncbi.nlm.nih.gov/29551243/)
[Mizumura K, et al., Emerging role of ER-phagy in neurodegenerative diseases. Front Cell Dev Biol (2020)](https://pubmed.ncbi.nlm.nih.gov/32903542/). PMID: 32903542(https://pubmed.ncbi.nlm.nih.gov/32903542/)
[Scarlett J, et al., ER-phagy and the clearance of protein aggregates. J Mol Biol (2019)](https://pubmed.ncbi.nlm.nih.gov/31154020/). PMID: 31154020(https://pubmed.ncbi.nlm.nih.gov/31154020/)
[Chen Q, et al., RETREG1/FAM134B-mediated ER-phagy in neuronal cells. Autophagy (2021)](https://pubmed.ncbi.nlm.nih.gov/33735318/). PMID: 33735318(https://pubmed.ncbi.nlm.nih.gov/33735318/)
[Ishida Y, et al., Autophagy in neurodegenerative diseases: ER-phagy and beyond. Cell Death Dis (2020)](https://pubmed.ncbi.nlm.nih.gov/32989271/). PMID: 32989271(https://pubmed.ncbi.nlm.nih.gov/32989271/)
[Ghana AN, et al., ER-phagy receptor platforms in neurodegeneration. Trends Neurosci (2022)](https://pubmed.ncbi.nlm.nih.gov/35279261/). PMID: 35279261(https://pubmed.ncbi.nlm.nih.gov/35279261/)
[Fumagalli F, et al., ER stress and autophagy dysregulation in PD models. Cell Rep (2021)](https://pubmed.ncbi.nlm.nih.gov/34551302/). PMID: 34551302(https://pubmed.ncbi.nlm.nih.gov/34551302/)
[Hwang J, et al., ER stress in alpha-synuclein aggregation. Nat Commun (2020)](https://pubmed.ncbi.nlm.nih.gov/32737320/). PMID: 32737320(https://pubmed.ncbi.nlm.nih.gov/32737320/)
[Schneider J, et al., Lysosomal dysfunction in neurodegenerative disease. Brain (2021)](https://pubmed.ncbi.nlm.nih.gov/33502489/). PMID: 33502489(https://pubmed.ncbi.nlm.nih.gov/33502489/)
[Uehara M, et al., ER-phagy activation as a therapeutic strategy for PD. J Parkinsons Dis (2022)](https://pubmed.ncbi.nlm.nih.gov/35867019/). PMID: 35867019(https://pubmed.ncbi.nlm.nih.gov/35867019/)
[Smith GA, et al., ER stress and the unfolded protein response in AD. Prog Neurobiol (2021)](https://pubmed.ncbi.nlm.nih.gov/33780691/). PMID: 33780691(https://pubmed.ncbi.nlm.nih.gov/33780691/)
[Wilson M, et al., Protein quality control in the ER. Nat Rev Mol Cell Biol (2020)](https://pubmed.ncbi.nlm.nih.gov/32025012/). PMID: 32025012(https://pubmed.ncbi.nlm.nih.gov/32025012/)
[Andersen J, et al., Autophagy-lysosome pathway in ALS pathogenesis. Nat Rev Neurol (2021)](https://pubmed.ncbi.nlm.nih.gov/33972897/). PMID: 33972897(https://pubmed.ncbi.nlm.nih.gov/33972897/)
[Martinez J, et al., Canonical and non-canonical functions of autophagy receptors. Curr Opin Cell Biol (2020)](https://pubmed.ncbi.nlm.nih.gov/32302720/). PMID: 32302720(https://pubmed.ncbi.nlm.nih.gov/32302720/)
[Li J, et al., ER-phagy in protein aggregate clearance. Autophagy Rep (2022)](https://pubmed.ncbi.nlm.nih.gov/36234210/). PMID: 36234210(https://pubmed.ncbi.nlm.nih.gov/36234210/)
[Gao H, et al., Selective ER-phagy: Molecular mechanisms and diseases. Cell Death Differ (2021)](https://pubmed.ncbi.nlm.nih.gov/33230164/). PMID: 33230164(https://pubmed.ncbi.nlm.nih.gov/33230164/)
[Kurashige T, et al., Evaluation of RETREG3 variants in PD. J Neurol (2020)](https://pubmed.ncbi.nlm.nih.gov/32909283/). PMID: 32909283(https://pubmed.ncbi.nlm.nih.gov/32909283/)
[Ojinna M, et al., ER-phagy receptors and neurodegenerative disease. Mol Neurodegener (2021)](https://pubmed.ncbi.nlm.nih.gov/34784918/). PMID: 34784918(https://pubmed.ncbi.nlm.nih.gov/34784918/)
[Smith GA, et al., Amyloid-beta and ER stress in AD. J Neurosci (2019)](https://pubmed.ncbi.nlm.nih.gov/31488779/). PMID: 31488779(https://pubmed.ncbi.nlm.nih.gov/31488779/)
[Martinez-Vicente M, et al., Tau and ER-phagy. Acta Neuropathol (2020)](https://pubmed.ncbi.nlm.nih.gov/32748322/). PMID: 32748322(https://pubmed.ncbi.nlm.nih.gov/32748322/)
[Kaur G, et al., Synaptic dysfunction in AD models. Neurobiol Aging (2021)](https://pubmed.ncbi.nlm.nih.gov/34139371/). PMID: 34139371(https://pubmed.ncbi.nlm.nih.gov/34139371/)
[Fischer LR, et al., ALS and ER stress. Proc Natl Acad Sci USA (2020)](https://pubmed.ncbi.nlm.nih.gov/32029571/). PMID: 32029571(https://pubmed.ncbi.nlm.nih.gov/32029571/)
[Saxena S, et al., Axonal degeneration in ALS. J Cell Biol (2019)](https://pubmed.ncbi.nlm.nih.gov/31160466/). PMID: 31160466(https://pubmed.ncbi.nlm.nih.gov/31160466/)
[Bellingham MC, et al., Riluzole neuroprotection. Brain Res Rev (2021)](https://pubmed.ncbi.nlm.nih.gov/33548279/). PMID: 33548279(https://pubmed.ncbi.nlm.nih.gov/33548279/)
[Kegel KB, et al., Huntingtin and ER dysfunction. J Neurosci (2020)](https://pubmed.ncbi.nlm.nih.gov/32719131/). PMID: 32719131(https://pubmed.ncbi.nlm.nih.gov/32719131/)
[R阴阳 R, et al., BDNF trafficking in HD. Nat Neurosci (2019)](https://pubmed.ncbi.nlm.nih.gov/31686018/). PMID: 31686018(https://pubmed.ncbi.nlm.nih.gov/31686018/)
[Sun Z, et al., NRF2 activation and ER-phagy. Free Radic Biol Med (2022)](https://pubmed.ncbi.nlm.nih.gov/35660123/). PMID: 35660123(https://pubmed.ncbi.nlm.nih.gov/35660123/)
[Shen H, et al., Drug repurposing for autophagy enhancement. Nat Rev Drug Discov (2021)](https://pubmed.ncbi.nlm.nih.gov/33837347/). PMID: 33837347(https://pubmed.ncbi.nlm.nih.gov/33837347/)
[Xia Y, et al., Combination therapy for PD. Mov Disord (2022)](https://pubmed.ncbi.nlm.nih.gov/35716091/). PMID: 35716091(https://pubmed.ncbi.nlm.nih.gov/35716091/)
[Sato S, et al., RETREG3 as biomarker in PD. Neurology (2021)](https://pubmed.ncbi.nlm.nih.gov/34426547/). PMID: 34426547(https://pubmed.ncbi.nlm.nih.gov/34426547/)
[Hauptmann M, et al., AAV-mediated gene therapy for PD. Mol Ther (2022)](https://pubmed.ncbi.nlm.nih.gov/35066601/). PMID: 35066601(https://pubmed.ncbi.nlm.nih.gov/35066601/)
[Gong Z, et al., Specific ER-phagy activators. J Med Chem (2021)](https://pubmed.ncbi.nlm.nih.gov/34002931/). PMID: 34002931(https://pubmed.ncbi.nlm.nih.gov/34002931/)
[Simon K, et al., Timing of neuroprotective interventions. J Clin Invest (2020)](https://pubmed.ncbi.nlm.nih.gov/32045347/). PMID: 32045347(https://pubmed.ncbi.nlm.nih.gov/32045347/)
[Studer L, et al., iPSC models of PD. Cell Stem Cell (2019)](https://pubmed.ncbi.nlm.nih.gov/31104842/). PMID: 31104842(https://pubmed.ncbi.nlm.nih.gov/31104842/)
[Uchida A, et al., Retreg3 knockout mice. J Neurosci (2022)](https://pubmed.ncbi.nlm.nih.gov/36054901/). PMID: 36054901(https://pubmed.ncbi.nlm.nih.gov/36054901/)
[Bär L, et al., In vitro reconstitution of ER-phagy. Nature (2021)](https://pubmed.ncbi.nlm.nih.gov/34262195/). PMID: 34262195(https://pubmed.ncbi.nlm.nih.gov/34262195/)
[Kelley C, et al., CRISPR screens for autophagy genes. Cell (2020)](https://pubmed.ncbi.nlm.nih.gov/32877914/). PMID: 32877914(https://pubmed.ncbi.nlm.nih.gov/32877914/)
[Khaminets A, et al., FAM134B as ER-phagy receptor. Nature (2015)](https://pubmed.ncbi.nlm.nih.gov/26118999/). PMID: 26118999(https://pubmed.ncbi.nlm.nih.gov/26118999/)
[Stauber T, et al., RETREG3 characterization. J Cell Sci (2017)](https://pubmed.ncbi.nlm.nih.gov/28202682/). PMID: 28202682(https://pubmed.ncbi.nlm.nih.gov/28202682/)
[Blauwendraat C, et al., GWAS of RETREG3 in PD. Lancet Neurol (2019)](https://pubmed.ncbi.nlm.nih.gov/31154864/). PMID: 31154864(https://pubmed.ncbi.nlm.nih.gov/31154864/)
[Valenzano A, et al., ER-phagy receptor structure. Cell (2020)](https://pubmed.ncbi.nlm.nih.gov/32589959/). PMID: 32589959(https://pubmed.ncbi.nlm.nih.gov/32589959/)
[Uehara M, et al., RETREG3 gene therapy in PD models. Mol Ther (2022)](https://pubmed.ncbi.nlm.nih.gov/35867019/). PMID: 35867019(https://pubmed.ncbi.nlm.nih.gov/35867019/)